Sankar Narayan Niranjan, MD
Nephrology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Niranjan’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$18,499
Medicare paid this office $18,499 for 127 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 121 | $17,134 | $100 |
Who their Medicare patients are
127 Original Medicare patients in 2024. Average age 80 · 85 and older 32% · Women 50% · Also on Medicaid 27% · Health risk score 1.98. At or below the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 53% · Coronary heart disease 46% · Heart failure 39% · Atrial fibrillation 37% · Depression 24% · COPD 16% · Cancer 15% · Stroke 15% · Dementia 9%.
The office billed $46,205, Medicare allowed $24,593 and paid $18,499; for 186 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 127 | 186 | 80 | 1.98 | $46,205 | $18,499 |
| 2023 | 326 | 996 | 76 | 4.08 | $490,555 | $121,706 |
| 2022 | 367 | 1,345 | 75 | 4.00 | $692,945 | $168,649 |
| 2021 | 388 | 1,570 | 74 | 4.44 | $690,235 | $190,137 |
| 2020 | 364 | 1,494 | 73 | 4.99 | $652,518 | $162,952 |
| 2019 | 394 | 1,847 | 73 | 4.97 | $879,640 | $203,857 |
| 2018 | 458 | 2,091 | 74 | 4.98 | $912,017 | $219,661 |
| 2017 | 614 | 2,531 | 74 | 4.54 | $972,418 | $245,843 |
| 2016 | 534 | 2,951 | 73 | 4.94 | $1,019,739 | $234,751 |
| 2015 | 571 | 5,483 | 74 | 4.60 | $957,816 | $250,506 |
| 2014 | 653 | 4,739 | 75 | 4.36 | $1,123,951 | $263,871 |
| 2013 | 702 | 4,295 | 73 | 4.83 | $1,152,412 | $261,929 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 21 | $40,366 | $290 |
| Return visit (30+ min) | 140 | $20,636 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 102 | $14,150 | $65 |
| Hemodialysis procedure with physician evaluation | 54 | $6,949 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $4,916 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $4,872 | $135 |
| New patient visit (45+ min) | 29 | $3,765 | $130 |
| Dialysis procedure including 1 evaluation | 19 | $2,621 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,936 | $102 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $657 | $41 |
| Manual urinalysis test with examination using microscope, non-automated | 12 | $47 | $4 |
2022: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 32 | $65,901 | $301 |
| Return visit (30+ min) | 133 | $20,680 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 117 | $15,820 | $59 |
| Hemodialysis procedure with physician evaluation | 74 | $10,746 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $7,142 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $7,112 | $148 |
| Dialysis procedure including 1 evaluation | 24 | $5,596 | $72 |
| Critical care, first 30-74 minutes | 29 | $5,525 | $173 |
| New patient visit (45+ min) | 41 | $5,182 | $126 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 15 | $5,004 | $250 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,701 | $113 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $418 | $32 |
| Manual urinalysis test with examination using microscope, non-automated | 20 | $80 | $4 |
2021: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 39 | $69,235 | $305 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 156 | $20,909 | $60 |
| Return visit (30+ min) | 107 | $18,460 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 84 | $14,588 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $11,142 | $86 |
| Hemodialysis procedure with physician evaluation | 82 | $10,189 | $61 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 16 | $6,094 | $254 |
| Critical care, first 30-74 minutes | 28 | $5,738 | $185 |
| Dialysis procedure including 1 evaluation | 25 | $4,709 | $74 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $3,439 | $115 |
| New patient visit (45+ min) | 26 | $3,213 | $124 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $589 | $31 |
| Remote evaluation of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related e/m service provided within t | 18 | $152 | $7 |
| Manual urinalysis test with examination using microscope, non-automated | 19 | $76 | $4 |
2020: 17 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 34 | $48,706 | $244 |
| Home dialysis services per month (20 years or older) | 15 | $21,374 | $206 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 134 | $17,782 | $61 |
| Hemodialysis procedure with physician evaluation | 92 | $11,782 | $62 |
| Return visit (30+ min) | 86 | $11,669 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $10,300 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $7,730 | $89 |
| Dialysis procedure including 1 evaluation | 30 | $6,507 | $73 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 42 | $5,766 | $118 |
| Critical care, first 30-74 minutes | 14 | $3,760 | $188 |
| New patient visit (45+ min) | 27 | $3,728 | $138 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 12 | $3,130 | $196 |
| Telephone medical discussion with physician, 11-20 minutes | 32 | $2,281 | $63 |
| Remote evaluation of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related e/m service provided within t | 44 | $554 | $10 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 34 | $489 | $13 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $468 | $33 |
| Manual urinalysis test with examination using microscope, non-automated | 17 | $68 | $4 |
2019: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 52 | $69,938 | $241 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 182 | $25,695 | $62 |
| Home dialysis services per month (20 years or older) | 13 | $23,215 | $202 |
| Return visit (30+ min) | 102 | $16,347 | $84 |
| Hemodialysis procedure with physician evaluation | 86 | $13,686 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $12,350 | $167 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 23 | $7,134 | $204 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 44 | $6,061 | $114 |
| Dialysis procedure including 1 evaluation | 24 | $5,891 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $4,682 | $88 |
| Critical care, first 30-74 minutes | 12 | $2,459 | $189 |
| New patient visit (45+ min) | 16 | $1,928 | $120 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $507 | $32 |
2018: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 46 | $71,763 | $235 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 246 | $37,816 | $61 |
| Home dialysis services per month (20 years or older) | 16 | $25,404 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $18,245 | $171 |
| Return visit (30+ min) | 104 | $16,913 | $88 |
| Hemodialysis procedure with physician evaluation | 109 | $14,078 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 49 | $6,397 | $112 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 21 | $6,167 | $199 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $4,642 | $88 |
| Dialysis procedure including 1 evaluation | 18 | $3,037 | $72 |
| New patient visit (45+ min) | 14 | $1,828 | $131 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 44 | $1,623 | $33 |
| Manual urinalysis test with examination using microscope, non-automated | 11 | $43 | $4 |
2017: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 60 | $63,484 | $239 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 331 | $47,522 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 120 | $21,812 | $169 |
| Home dialysis services per month (20 years or older) | 17 | $20,873 | $199 |
| Return visit (30+ min) | 111 | $17,954 | $86 |
| Hemodialysis procedure with physician evaluation | 131 | $15,969 | $60 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 29 | $10,644 | $201 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 25 | $9,313 | $239 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $8,353 | $88 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $7,076 | $114 |
| Dialysis procedure including 1 evaluation | 39 | $5,853 | $72 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 80 | $2,957 | $32 |
| New patient visit (45+ min) | 22 | $2,863 | $130 |
2016: 16 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 65 | $76,355 | $234 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 275 | $39,837 | $59 |
| Home dialysis services per month (20 years or older) | 14 | $20,250 | $197 |
| Hemodialysis procedure with physician evaluation | 129 | $17,618 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 96 | $17,167 | $167 |
| Return visit (30+ min) | 108 | $16,747 | $83 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 33 | $8,769 | $183 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 66 | $8,764 | $111 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 17 | $7,379 | None |
| Dialysis procedure including 1 evaluation | 40 | $7,034 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $3,845 | $85 |
| New patient visit (45+ min) | 23 | $2,856 | $124 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 62 | $2,267 | $32 |
| Short return visit | 14 | $785 | $33 |
| Injection of drug or substance under skin or into muscle | 17 | $644 | $21 |
| Blood count, hemoglobin | 11 | $51 | $3 |
2015: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 56 | $62,395 | $239 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 318 | $51,270 | $61 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 34 | $28,440 | None |
| Return visit (30+ min) | 105 | $19,007 | $88 |
| Hemodialysis procedure with physician evaluation | 132 | $18,557 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $17,091 | $171 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 73 | $9,930 | $114 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 28 | $9,271 | $202 |
| Dialysis procedure including 1 evaluation | 34 | $5,860 | $72 |
| Short return visit | 32 | $3,804 | $37 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 60 | $2,686 | $33 |
| Injection of drug or substance under skin or into muscle | 34 | $2,630 | $22 |
| New patient visit (45+ min) | 17 | $2,214 | $130 |
| Blood count, hemoglobin | 30 | $288 | $3 |
2014: 15 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 58 | $88,576 | $232 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 349 | $47,114 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 156 | $27,864 | $167 |
| Hemodialysis procedure with physician evaluation | 171 | $22,502 | $60 |
| Return visit (30+ min) | 112 | $21,574 | $84 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 41 | $19,432 | None |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 27 | $6,435 | $201 |
| Dialysis procedure including 1 evaluation | 31 | $5,087 | $71 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $3,002 | $111 |
| Short return visit | 44 | $2,822 | $37 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 76 | $2,764 | $30 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $2,506 | $86 |
| New patient visit (45+ min) | 17 | $2,032 | $120 |
| Injection of drug or substance under skin or into muscle | 41 | $1,917 | $22 |
| Blood count, hemoglobin | 45 | $273 | $3 |
2013: 15 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 170 | $97,494 | $232 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 313 | $37,469 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 160 | $29,793 | $165 |
| Hemodialysis procedure with physician evaluation | 150 | $21,391 | $59 |
| Return visit (30+ min) | 105 | $19,955 | $84 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 31 | $15,540 | None |
| Home dialysis services per month (20 years or older) | 23 | $12,001 | $197 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 26 | $5,973 | $199 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 142 | $5,406 | $32 |
| Dialysis procedure including 1 evaluation | 37 | $4,391 | $69 |
| New patient visit (45+ min) | 26 | $3,579 | $138 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,818 | $113 |
| Short return visit | 30 | $1,834 | $37 |
| Injection of drug or substance under skin or into muscle | 31 | $1,581 | $22 |
| Blood count, hemoglobin | 33 | $212 | $3 |
Medicaid work
$1,379 in 2024
Medicaid paid $1,379 for 112 billed services this clinician did in 2024, up to 39 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 112 | $1,379 |
| 2024 | 112 | 1 | 39 | $1,379 |
| 2023 | 690 | 4 | 26 | $18,444 |
| 2022 | 1,369 | 11 | 26 | $75,543 |
| 2021 | 967 | 9 | 27 | $36,425 |
| 2020 | 666 | 4 | 25 | $35,653 |
| 2019 | 980 | 5 | 29 | $42,084 |
| 2018 | 1,378 | 8 | 30 | $39,318 |
See the largest Medicaid services in earlier years
2023
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 107 | $8,887 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 92 | $3,436 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 242 | $3,340 |
| Return visit (30+ min) | 249 | $2,781 |
2022
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 475 | $41,079 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 225 | $19,995 |
| Injection, epoetin alfa, 100 units (for esrd on dialysis) | 117 | $4,507 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 261 | $4,435 |
| Return visit (30+ min) | 133 | $2,578 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 56 | $2,554 |
| Iron sucrose injection | 39 | $396 |
| TOBACCO NON-USER | 12 | $0 |
| Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 13 | $0 |
| Most recent diastolic blood pressure < 90 mmhg | 26 | $0 |
| Bp scrn perf rec interval | 12 | $0 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 272 | $22,906 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 352 | $6,139 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 156 | $5,041 |
| Return visit (30+ min) | 112 | $1,828 |
| 1ST HOSP IP/OBS HIGH 75 | 13 | $512 |
| TOBACCO NON-USER | 16 | $0 |
| Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 17 | $0 |
| Most recent diastolic blood pressure < 90 mmhg | 16 | $0 |
| Bp scrn perf rec interval | 13 | $0 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 257 | $26,898 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 270 | $4,858 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 97 | $3,083 |
| Return visit (30+ min) | 42 | $815 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 283 | $29,708 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 446 | $6,924 |
| Return visit (30+ min) | 133 | $2,348 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 94 | $2,091 |
| 1ST HOSP IP/OBS HIGH 75 | 24 | $1,013 |
2018
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 279 | $27,669 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 220 | $5,696 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 680 | $4,172 |
| Return visit (30+ min) | 130 | $1,365 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $416 |
| TOBACCO NON-USER | 16 | $0 |
| Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 12 | $0 |
| Most recent diastolic blood pressure < 90 mmhg | 29 | $0 |
Drugs they prescribed that Part D paid
$98,316
Pharmacies billed $98,316 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 639) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
492 generic and fewer than 11 brand-name prescriptions · $98,316 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Farxiga | 78 | $60,941 | $781 |
| Jardiance | 15 | $12,597 | $840 |
| Clinolipid | 15 | $3,630 | $242 |
| Calcitriol | 65 | $941 | $14 |
| Torsemide | 36 | $831 | $23 |
See all 17 drugs
| Farxiga | 78 | $60,941 | $781 |
| Jardiance | 15 | $12,597 | $840 |
| Clinolipid | 15 | $3,630 | $242 |
| Calcitriol | 65 | $941 | $14 |
| Torsemide | 36 | $831 | $23 |
| Amlodipine Besylate | 104 | $526 | $5 |
| Calcium Acetate | 15 | $495 | $33 |
| Potassium Chloride | 15 | $354 | $24 |
| Spironolactone | 40 | $230 | $6 |
| Tamsulosin | 15 | $223 | $15 |
| Furosemide | 31 | $180 | $6 |
| Allopurinol | 13 | $162 | $12 |
| Doxazosin Mesylate | 12 | $141 | $12 |
| Losartan | 13 | $89 | $7 |
| Lisinopril | 18 | $82 | $5 |
| Atenolol | 12 | $29 | $2 |
| Ramipril | 14 | $18 | $1 |
Year by year
| 2024 | 639 | 132 | 0% (0) | None | $98,316 |
| 2023 | 915 | 185 | 0% (0) | 26% | $133,201 |
| 2022 | 858 | 171 | 0% (0) | 25% | $209,420 |
| 2021 | 784 | 155 | 0% (0) | 22% | $167,259 |
| 2020 | 712 | 126 | 0% (0) | 21% | $118,764 |
| 2019 | 850 | 139 | None | 25% | $156,505 |
| 2018 | 849 | 135 | 0% (0) | None | $179,515 |
| 2017 | 1,240 | 130 | 0% (0) | 45% | $345,169 |
| 2016 | 1,121 | 121 | 0% (0) | None | $318,306 |
| 2015 | 1,296 | 127 | 2% (20) | 36% | $320,551 |
| 2014 | 1,322 | 127 | 2% (28) | 33% | $192,283 |
| 2013 | 1,436 | 171 | 2% (21) | 34% | $232,080 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Farxiga | 68 | $48,932 | $720 |
| Clinolipid | 61 | $16,902 | $277 |
| Sevelamer Carbonate | 50 | $7,797 | $156 |
| Prosol | 30 | $4,450 | $148 |
| Januvia | 21 | $4,421 | $211 |
| Calcium Acetate | 26 | $1,495 | $57 |
| Calcitriol | 74 | $1,462 | $20 |
| Torsemide | 51 | $1,403 | $28 |
| Potassium Chloride | 23 | $1,132 | $49 |
| Amlodipine Besylate | 112 | $754 | $7 |
| Spironolactone | 41 | $417 | $10 |
| Furosemide | 38 | $311 | $8 |
| Tamsulosin | 14 | $282 | $20 |
| Allopurinol | 15 | $204 | $14 |
| Losartan | 12 | $149 | $12 |
| Lisinopril | 23 | $127 | $6 |
| Carvedilol | 17 | $87 | $5 |
| Atenolol | 14 | $62 | $4 |
2022: 25 drugs
| Velphoro | 19 | $74,624 | $3,928 |
| Sevelamer Carbonate | 35 | $12,641 | $361 |
| Farxiga | 19 | $12,216 | $643 |
| Prosol | 79 | $11,458 | $145 |
| Clinolipid | 20 | $5,727 | $286 |
| Calcium Acetate | 28 | $3,695 | $132 |
| Edarbyclor | 11 | $2,523 | $229 |
| Januvia | 12 | $2,220 | $185 |
| Calcitriol | 46 | $1,541 | $34 |
| Torsemide | 50 | $1,500 | $30 |
| Diltiazem 24hr Er (Cd) | 13 | $1,008 | $78 |
| Amlodipine Besylate | 96 | $724 | $8 |
| Hydralazine | 15 | $651 | $43 |
| Spironolactone | 35 | $431 | $12 |
| Lisinopril | 28 | $322 | $11 |
| Losartan | 14 | $314 | $22 |
| Valsartan | 14 | $306 | $22 |
| Furosemide | 21 | $263 | $13 |
| Doxazosin Mesylate | 14 | $232 | $17 |
| Tamsulosin | 11 | $172 | $16 |
| Enalapril Maleate | 11 | $152 | $14 |
| Allopurinol | 13 | $136 | $10 |
| Carvedilol | 15 | $100 | $7 |
| Ciprofloxacin | 13 | $49 | $4 |
| Atenolol | 15 | $45 | $3 |
2021: 22 drugs
| Velphoro | 27 | $65,255 | $2,417 |
| Auryxia | 12 | $27,932 | $2,328 |
| Sevelamer Carbonate | 35 | $16,128 | $461 |
| Prosol | 59 | $9,010 | $153 |
| Calcium Acetate | 18 | $2,933 | $163 |
| Edarbyclor | 13 | $2,895 | $223 |
| Clinisol | 13 | $2,364 | $182 |
| Calcitriol | 44 | $1,543 | $35 |
| Torsemide | 38 | $885 | $23 |
| Spironolactone | 63 | $748 | $12 |
| Amlodipine Besylate | 93 | $747 | $8 |
| Diltiazem 24hr Er (Cd) | 11 | $639 | $58 |
| Hydralazine | 15 | $479 | $32 |
| Losartan | 30 | $390 | $13 |
| Doxazosin Mesylate | 13 | $344 | $26 |
| Metoprolol | 13 | $287 | $22 |
| Lisinopril | 16 | $207 | $13 |
| Allopurinol | 11 | $182 | $17 |
| Furosemide | 14 | $124 | $9 |
| Tamsulosin | 14 | $92 | $7 |
| Gabapentin | 16 | $88 | $6 |
| Prednisone | 11 | $72 | $7 |
2020: 16 drugs
| Auryxia | 23 | $44,684 | $1,943 |
| Sevelamer Carbonate | 30 | $14,644 | $488 |
| Intralipid | 12 | $4,787 | $399 |
| Prosol | 30 | $4,437 | $148 |
| Calcium Acetate | 20 | $3,165 | $158 |
| Edarbyclor | 13 | $2,815 | $217 |
| Calcitriol | 49 | $1,334 | $27 |
| Amlodipine Besylate | 108 | $1,011 | $9 |
| Torsemide | 59 | $999 | $17 |
| Losartan | 21 | $413 | $20 |
| Spironolactone | 39 | $388 | $10 |
| Doxazosin Mesylate | 12 | $333 | $28 |
| Terazosin | 16 | $323 | $20 |
| Furosemide | 14 | $92 | $7 |
| Lisinopril | 16 | $87 | $5 |
| Prednisone | 12 | $54 | $4 |
2019: 19 drugs
| Auryxia | 27 | $67,608 | $2,504 |
| Intralipid | 44 | $13,383 | $304 |
| Sevelamer Carbonate | 29 | $7,414 | $256 |
| Prosol | 52 | $6,567 | $126 |
| Calcium Acetate | 32 | $2,660 | $83 |
| Calcitriol | 65 | $1,461 | $22 |
| Torsemide | 57 | $1,126 | $20 |
| Amlodipine Besylate | 104 | $1,025 | $10 |
| Hydralazine | 17 | $944 | $56 |
| Lidocaine-Prilocaine | 23 | $627 | $27 |
| Midodrine | 14 | $556 | $40 |
| Spironolactone | 37 | $415 | $11 |
| Terazosin | 24 | $398 | $17 |
| Doxazosin Mesylate | 11 | $273 | $25 |
| Metoprolol | 19 | $271 | $14 |
| Losartan | 13 | $242 | $19 |
| Furosemide | 25 | $147 | $6 |
| Atenolol | 21 | $122 | $6 |
| Lisinopril | 13 | $101 | $8 |
2018: 20 drugs
| Renvela | 30 | $55,522 | $1,851 |
| Auryxia | 23 | $37,661 | $1,637 |
| Sevelamer Carbonate | 27 | $27,654 | $1,024 |
| Intralipid | 52 | $13,443 | $259 |
| Prosol | 20 | $3,583 | $179 |
| Calcium Acetate | 33 | $2,935 | $89 |
| Calcitriol | 70 | $1,712 | $24 |
| Lidocaine-Prilocaine | 15 | $1,277 | $85 |
| Paricalcitol | 20 | $1,257 | $63 |
| Chlorthalidone | 22 | $970 | $44 |
| Polyethylene Glycol 3350 | 13 | $903 | $69 |
| Torsemide | 50 | $766 | $15 |
| Doxazosin Mesylate | 27 | $561 | $21 |
| Amlodipine Besylate | 81 | $500 | $6 |
| Furosemide | 38 | $202 | $5 |
| Metoprolol | 16 | $196 | $12 |
| Terazosin | 18 | $186 | $10 |
| Allopurinol | 16 | $138 | $9 |
| Pantoprazole | 17 | $121 | $7 |
| Carvedilol | 11 | $80 | $7 |
2017: 30 drugs
| Renvela | 67 | $95,642 | $1,427 |
| Sensipar | 49 | $89,353 | $1,824 |
| Prosol | 196 | $45,587 | $233 |
| Auryxia | 19 | $23,825 | $1,254 |
| Intralipid | 29 | $6,773 | $234 |
| Calcium Acetate | 33 | $5,376 | $163 |
| Eliquis | 13 | $5,150 | $396 |
| Dextrose in Water | 55 | $2,488 | $45 |
| Midodrine | 23 | $1,493 | $65 |
| Lidocaine-Prilocaine | 31 | $1,441 | $46 |
| Paricalcitol | 11 | $1,051 | $96 |
| Chlorthalidone | 17 | $882 | $52 |
| Valsartan | 23 | $803 | $35 |
| Calcitriol | 30 | $626 | $21 |
| Torsemide | 39 | $597 | $15 |
| Doxazosin Mesylate | 20 | $494 | $25 |
| Amlodipine Besylate | 74 | $431 | $6 |
| Metoprolol | 20 | $425 | $21 |
| Valsartan-Hydrochlorothiazide | 26 | $402 | $15 |
| Losartan | 34 | $361 | $11 |
| Diltiazem 24hr Er | 14 | $342 | $24 |
| Furosemide | 51 | $184 | $4 |
| Pantoprazole | 22 | $168 | $8 |
| Carvedilol | 37 | $166 | $4 |
| Omeprazole | 13 | $166 | $13 |
| Lisinopril | 18 | $137 | $8 |
| Allopurinol | 13 | $105 | $8 |
| Trazodone | 11 | $88 | $8 |
| Spironolactone | 13 | $83 | $6 |
| Zolpidem | 14 | $47 | $3 |
2016: 26 drugs
| Renvela | 91 | $129,962 | $1,428 |
| Sensipar | 71 | $97,671 | $1,376 |
| Fosrenol | 12 | $37,664 | $3,139 |
| Prosol | 92 | $16,733 | $182 |
| Calcium Acetate | 79 | $11,015 | $139 |
| Chlorthalidone | 29 | $1,390 | $48 |
| Valsartan | 22 | $881 | $40 |
| Calcitriol | 39 | $755 | $19 |
| Torsemide | 44 | $674 | $15 |
| Diltiazem 24hr Er | 15 | $504 | $34 |
| Losartan | 34 | $328 | $10 |
| Valsartan-Hydrochlorothiazide | 19 | $324 | $17 |
| Amlodipine Besylate | 70 | $323 | $5 |
| Potassium Chloride | 18 | $276 | $15 |
| Omeprazole | 33 | $201 | $6 |
| Carvedilol | 37 | $181 | $5 |
| Spironolactone | 34 | $174 | $5 |
| Doxazosin Mesylate | 15 | $171 | $11 |
| Terazosin | 17 | $166 | $10 |
| Lisinopril | 35 | $164 | $5 |
| Atorvastatin | 15 | $156 | $10 |
| Furosemide | 41 | $130 | $3 |
| Allopurinol | 12 | $101 | $8 |
| Pantoprazole | 21 | $92 | $4 |
| Atenolol | 11 | $55 | $5 |
| Lactulose | 13 | $34 | $3 |
2015: 38 drugs
| Renvela | 78 | $110,366 | $1,415 |
| Sensipar | 94 | $101,744 | $1,082 |
| Fosrenol | 28 | $54,345 | $1,941 |
| Calcium Acetate | 73 | $13,312 | $182 |
| Prosol | 49 | $7,711 | $157 |
| Nexium | 12 | $2,975 | $248 |
| Lyrica | 14 | $2,854 | $204 |
| Diovan | 11 | $2,655 | $241 |
| Clonidine | 13 | $2,615 | $201 |
| Valsartan | 13 | $1,404 | $108 |
| Labetalol | 12 | $1,226 | $102 |
| Chlorthalidone | 21 | $1,011 | $48 |
| Calcitriol | 48 | $758 | $16 |
| Valsartan-Hydrochlorothiazide | 17 | $704 | $41 |
| Torsemide | 33 | $557 | $17 |
| Hydralazine | 23 | $422 | $18 |
| Midodrine | 12 | $410 | $34 |
| Doxazosin Mesylate | 23 | $389 | $17 |
| Losartan | 36 | $382 | $11 |
| Pravastatin | 14 | $375 | $27 |
| Amlodipine Besylate | 87 | $364 | $4 |
| Levothyroxine | 21 | $285 | $14 |
| Insulin | 11 | $284 | $26 |
| Furosemide | 63 | $278 | $4 |
| Atorvastatin | 25 | $205 | $8 |
| Carvedilol | 34 | $203 | $6 |
| Spironolactone | 25 | $196 | $8 |
| Omeprazole | 28 | $193 | $7 |
| Lisinopril | 49 | $181 | $4 |
| Potassium Chloride | 11 | $172 | $16 |
| Metoprolol | 11 | $146 | $13 |
| Gabapentin | 23 | $138 | $6 |
| Tramadol | 18 | $107 | $6 |
| Escitalopram | 16 | $97 | $6 |
| Pantoprazole | 18 | $96 | $5 |
| Lactulose | 12 | $68 | $6 |
| Metoprolol | 13 | $60 | $5 |
| Pramipexole Dihydrochloride | 12 | $54 | $5 |
2014: 39 drugs
| Sensipar | 57 | $47,789 | $838 |
| Renvela | 42 | $37,365 | $890 |
| Fosrenol | 15 | $31,496 | $2,100 |
| Calcium Acetate | 68 | $14,039 | $206 |
| Prosol | 72 | $11,497 | $160 |
| Intralipid | 22 | $6,781 | $308 |
| Diovan | 28 | $5,584 | $199 |
| Clonidine | 13 | $2,570 | $198 |
| Calcitriol | 61 | $1,514 | $25 |
| Metoprolol | 32 | $711 | $22 |
| Diltiazem 24hr Er | 12 | $646 | $54 |
| Losartan | 51 | $585 | $11 |
| Pravastatin | 13 | $465 | $36 |
| Polyethylene Glycol 3350 | 15 | $462 | $31 |
| Omeprazole | 26 | $449 | $17 |
| Amlodipine Besylate | 86 | $443 | $5 |
| Chlorthalidone | 12 | $420 | $35 |
| Quinapril | 14 | $408 | $29 |
| Torsemide | 30 | $388 | $13 |
| Fenofibrate | 12 | $372 | $31 |
| Doxazosin Mesylate | 15 | $340 | $23 |
| Levothyroxine | 22 | $307 | $14 |
| Spironolactone | 40 | $305 | $8 |
| Carvedilol | 35 | $299 | $9 |
| Furosemide | 46 | $280 | $6 |
| Escitalopram | 17 | $248 | $15 |
| Hydralazine | 19 | $235 | $12 |
| Tramadol | 26 | $181 | $7 |
| Pantoprazole | 21 | $160 | $8 |
| Lovastatin | 14 | $160 | $11 |
| Lisinopril | 31 | $150 | $5 |
| Gabapentin | 15 | $131 | $9 |
| Pramipexole Dihydrochloride | 12 | $122 | $10 |
| Atorvastatin | 12 | $111 | $9 |
| Metolazone | 13 | $110 | $8 |
| Metoprolol | 20 | $99 | $5 |
| Simvastatin | 21 | $97 | $5 |
| Minoxidil | 11 | $91 | $8 |
| Clonazepam | 11 | $84 | $8 |
2013: 43 drugs
| Renvela | 66 | $66,749 | $1,011 |
| Sensipar | 62 | $59,099 | $953 |
| Calcium Acetate | 87 | $18,751 | $216 |
| Fosrenol | 18 | $17,994 | $1,000 |
| Diovan | 32 | $5,557 | $174 |
| Lantus | 25 | $3,829 | $153 |
| Lantus Solostar | 11 | $2,819 | $256 |
| Exforge | 11 | $1,980 | $180 |
| Novolog | 12 | $1,828 | $152 |
| Calcitriol | 37 | $1,387 | $37 |
| Lidocaine-Prilocaine | 36 | $1,283 | $36 |
| Diltiazem 24hr Er | 26 | $1,122 | $43 |
| Labetalol | 14 | $1,054 | $75 |
| Losartan | 54 | $850 | $16 |
| Escitalopram | 18 | $722 | $40 |
| Megestrol Acetate | 15 | $682 | $45 |
| Amlodipine Besylate | 69 | $639 | $9 |
| Metoprolol | 21 | $593 | $28 |
| Torsemide | 26 | $563 | $22 |
| Chlorthalidone | 24 | $526 | $22 |
| Omeprazole | 30 | $512 | $17 |
| Fenofibrate | 13 | $510 | $39 |
| Diltiazem 24hr Cd | 11 | $423 | $38 |
| Carvedilol | 43 | $407 | $9 |
| Losartan-Hydrochlorothiazide | 19 | $395 | $21 |
| Bd Ultra-Fine Pen Needle | 12 | $387 | $32 |
| Doxazosin Mesylate | 32 | $364 | $11 |
| Lisinopril | 38 | $341 | $9 |
| Insulin | 12 | $327 | $27 |
| Metolazone | 18 | $308 | $17 |
| Potassium Chloride | 17 | $297 | $17 |
| Spironolactone | 14 | $252 | $18 |
| Hydralazine | 17 | $236 | $14 |
| Furosemide | 39 | $236 | $6 |
| Hydroxyzine | 12 | $226 | $19 |
| Pramipexole Dihydrochloride | 13 | $206 | $16 |
| Isosorbide Mononitrate Er | 14 | $188 | $13 |
| Levothyroxine | 22 | $178 | $8 |
| Metoprolol | 23 | $155 | $7 |
| Tramadol | 20 | $146 | $7 |
| Simvastatin | 12 | $71 | $6 |
| Zolpidem | 14 | $69 | $5 |
| Terazosin | 12 | $60 | $5 |
Money from drug and device companies
$122 in 2025
| 2025 | 1 | 2 | None | $122 |
| 2024 | 6 | 12 | None | $444 |
| 2023 | 10 | 11 | None | $497 |
| 2022 | 10 | 11 | None | $337 |
| 2020 | 3 | 3 | None | $106 |
| 2019 | 8 | 18 | None | $1,682 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Idorsia Pharmaceuticals US | Tryvio | $122 | 2 payments
|
See all 2 published payments
| Idorsia Pharmaceuticals US | Meals · 2025-08-08 | Tryvio | $27 |
| Idorsia Pharmaceuticals US | Meals · 2025-07-22 | Tryvio | $95 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $444
| Amgen | Aranesp | $177 | 5 payments
|
| Baxter Healthcare | Renal - Chronic | $149 | 2 payments
|
| Akebia Therapeutics | Vafseo | $49 | 2 payments
|
| Novartis Pharmaceuticals | None | $28 | 1 payment
|
| Lilly USA | Jardiance | $22 | 1 payment
|
| Novo Nordisk | Ozempic | $20 | 1 payment
|
2023: $497
| Amgen | Parsabiv | $162 | 2 payments
|
| Baxter Healthcare | None | $125 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $64 | 1 payment
|
| GlaxoSmithKline | Benlysta | $28 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $26 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $21 | 1 payment
|
| Ardelyx | Ibsrela | $20 | 1 payment
|
| Travere Therapeutics | None | $19 | 1 payment
|
| Calliditas Therapeutics US | Tarpeyo | $18 | 1 payment
|
| Vifor Pharma | Veltassa | $14 | 1 payment
|
2022: $337
| Travere Therapeutics | None | $83 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $75 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $35 | 2 payments
|
| Mallinckrodt Hospital Products | Terlivaz | $30 | 1 payment
|
| GlaxoSmithKline | Benlysta | $29 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $21 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $18 | 1 payment
|
| Akebia Therapeutics | None | $17 | 1 payment
|
| Vifor Pharma | Veltassa | $15 | 1 payment
|
| Baxter Healthcare | Renal - Pd | $14 | 1 payment
|
2020: $106
| Bard Peripheral Vascular | Covera | $73 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $19 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $15 | 1 payment
|
2019: $1,682
| AstraZeneca UK | None | $1,336 | 8 payments
|
| Baxter Healthcare | Renal - Non Product Related | $138 | 2 payments
|
| Alexion Pharmaceuticals | None | $72 | 1 payment
|
| Shire North American Group | Gattex | $47 | 2 payments
|
| Amgen | Parsabiv | $34 | 2 payments
|
| Fresenius USA Marketing | None | $20 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $18 | 1 payment
|
| Mallinckrodt Enterprises | Acthar | $16 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca Pharmaceuticals LP · A Phase 2b Multicenter Randomised Double Blind Placebo Controlled Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricemia · 2019 | Their institution | $13,918 |
| AstraZeneca Pharmaceuticals LP · A Phase 2b Multicenter Randomised Double Blind Placebo Controlled Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricemia · 2020 | Their institution | $8,715 |
| AstraZeneca Pharmaceuticals LP · A Phase 2b Multicenter Randomised Double Blind Placebo Controlled Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricemia · 2021 | Their institution | $5,150 |
| AstraZeneca Pharmaceuticals LP · A Phase 2b Multicenter Randomised Double Blind Placebo Controlled Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricemia · 2023 | Their institution | $4,752 |
Professional record
- NPI
- 1497752802
- Licence
- CT 041816
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CT 001418161
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2005-06-30
- NPI last updated
- 2025-03-27
- NPI record certified
- 2025-03-27
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 35 Jolley Dr, Bloomfield, CT, 06002